Disease · MONDO_0005011
Comparisons in its trials213
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 213
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Vedolizumab 300 mg (UC) vs Vedolizumab 300 mg (CD): Number of Participants With at Least One Clinically Significant Electrocardiogram (ECG) Findings | 7 of 894 | 7 of 1,349 | 2,243 | NCT00790933 | Trial comparisons |
| Part 1 (OLE): Etrolizumab vs Part 2 (PML SM): deaths from any cause | 3 of 751 | 1 of 359 | 1,110 | NCT02403323 | Trial comparisons |
| Part 1 (OLE): Etrolizumab vs Part 2 (PML SM): serious adverse events | 206 of 751 | 1 of 359 | 1,110 | NCT02403323 | Trial comparisons |
| Treatment 1 vs Treatment 2: deaths from any cause | 0 of 416 | 0 of 207 | 623 | NCT03440372 | Trial comparisons |
| Treatment 1 vs Treatment 2: serious adverse events | 27 of 416 | 10 of 207 | 623 | NCT03440372 | Trial comparisons |
| Ozanimod vs Placebo: deaths from any cause | 0 of 404 | 0 of 202 | 606 | NCT03440385 | Trial comparisons |
| Ozanimod vs Placebo: serious adverse events | 24 of 404 | 11 of 202 | 606 | NCT03440385 | Trial comparisons |
| Maintenance Period: Treat to Target vs Maintenance Period: Routine Care: Number of Participants With Adverse Events (AEs) That Occurred in Participants Administered With Ustekinumab up to Week 48 | 188 of 219 | 179 of 221 | 440 | NCT03107793 | Trial comparisons |
| Certolizumab Pegol vs Placebo: serious adverse events | 12 of 223 | 8 of 215 | 438 | NCT00552058 | Trial comparisons |
| Vedolizumab vs Placebo: serious adverse events | 13 of 209 | 16 of 207 | 416 | NCT01224171 | Trial comparisons |
| Adalimumab vs Ustekinumab: deaths from any cause | 1 of 195 | 0 of 191 | 386 | NCT03464136 | Trial comparisons |
| Adalimumab vs Ustekinumab: serious adverse events | 38 of 195 | 29 of 191 | 386 | NCT03464136 | Trial comparisons |
| CT-P13 SC 120 mg vs Placebo: Percentage of Patients Achieving CDAI-100 Response at Week 54 | 152 of 231 | 43 of 112 | 343 | NCT03945019 | Trial comparisons |
| CT-P13 SC 120 mg vs Placebo: Percentage of Patients Achieving Clinical Remission (Based on AP and SF) at Week 54 | 131 of 231 | 35 of 112 | 343 | NCT03945019 | Trial comparisons |
| CT-P13 SC 120 mg vs Placebo: Percentage of Patients Achieving Endoscopic Response (Based on Central SES-CD) at Week 54 | 118 of 231 | 20 of 112 | 343 | NCT03945019 | Trial comparisons |
| CT-P13 SC 120 mg vs Placebo: Percentage of Patients Achieving Clinical Remission (Based on CDAI) at Week 54 | 144 of 231 | 36 of 112 | 343 | NCT03945019 | Trial comparisons |
| CT-P13 SC 120 mg vs Placebo SC: Percentage of Patients Achieving Endoscopic Remission (Based on Central SES-CD) at Week 54 | 80 of 231 | 12 of 112 | 343 | NCT03945019 | Trial comparisons |
| RHB-104 vs Placebo: Durable Remission Week 26 Through Week 52 | 33 of 166 | 21 of 165 | 331 | NCT01951326 | Trial comparisons |
| RHB-104 vs Placebo: Remission at Week 26 | 61 of 166 | 37 of 165 | 331 | NCT01951326 | Trial comparisons |
| RHB-104 vs Placebo: Response at Week 16 | 79 of 166 | 60 of 165 | 331 | NCT01951326 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005011/comparisons